Emergency Contraception Clinical Trial
Official title:
Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial
This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.
Objective: To compare the percentage of pregnancies prevented by LNG co-administered with piroxicam or placebo for oral emergency contraception (EC) by a randomised controlled trial. Hypothesis to be tested: LNG plus piroxicam has higher percentage of pregnancies prevented compared with LNG plus placebo for oral emergency contraception. Design and subjects: This will be a prospective, randomised placebo-controlled clinical trial. Women attending the Family Planning Association of Hong Kong for oral EC within 72 hours of unprotected sexual intercourse will be recruited. Study instruments: Prospective follow-up of subjects in the clinic for the primary and secondary outcomes. Interventions: Eligible subjects will be randomised to receive one of the two treatment regimens, i.e. Group A: a single dose of LNG 1.5 mg and piroxicam 40 mg, or Group B: a single dose of LNG 1.5mg and placebo under direct supervision. Main outcome measures: Percentage of pregnancies prevented (PPP) is the primary outcome measure. Secondary outcome measures include failure rate, rate of occurrence of side effects and pattern of the menstruation following EC. Data analysis:The percentage of pregnancies prevented, failure rate and rate of occurrence of side effects will be compared between groups using Fisher-Exact test. Continuous variables regarding menstrual pattern between the two groups will be compared by Mann-Whitney U test. Expected results: LNG plus piroxicam has a higher PPP compared to LNG plus placebo. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00271583 -
Efficacy Trial of CDB 2914 for Emergency Contraception
|
Phase 2/Phase 3 | |
| Completed |
NCT00777556 -
Emergency Contraception Actual Use Study
|
Phase 3 | |
| Completed |
NCT00677755 -
Medical Abortion for Emergency Contraception Failure
|
N/A | |
| Recruiting |
NCT06162611 -
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
|
Phase 4 | |
| Completed |
NCT00411684 -
Safety and Efficacy of CDB-2914 for Emergency Contraception
|
Phase 3 | |
| Completed |
NCT01569737 -
Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
|
||
| Completed |
NCT03208985 -
A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
|
Phase 3 | |
| Completed |
NCT02078414 -
Continued Use of Effective Contraception After Use of Emergency Contraception
|
||
| Completed |
NCT01569113 -
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.
|
Phase 4 | |
| Completed |
NCT01963962 -
Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception
|
N/A | |
| Recruiting |
NCT03120728 -
Application for the Etonogestrel/Ethinyl Estradiol Ring
|
Phase 4 | |
| Active, not recruiting |
NCT02076217 -
Quick Start of Highly Effective Contraception
|
||
| Not yet recruiting |
NCT04172584 -
Awareness & Use of Emergency Contraception
|
||
| Completed |
NCT03395756 -
Depot Medroxyprogesterone Acetate as Emergency Contraception
|
Early Phase 1 |